| Literature DB >> 25061523 |
Ya-Jui Hsu1, Yi-Ting Hsieh1, Po-Ting Yeh1, Jehn-Yu Huang1, Chung-May Yang1.
Abstract
Purpose. To investigate the clinical features, surgical outcomes, and prognostic factors of combined rhegmatogenous and tractional detachment (combined RD) in proliferative diabetic retinopathy (PDR) in recent years. Methods. Medical records of PDR and combined RD treated with vitrectomy from 2008 to 2013 were retrospectively reviewed. Results. A total of 57 eyes from 49 patients were included. Nine eyes had received panretinal photocoagulation (PRP) and 7 eyes had intravitreal bevacizumab (IVB) within 3 months before RD developed. Thirty-eight eyes (66.7%) had ≧3 sites of broad adhesion of fibrovascular proliferation (FVP). Thirty-three eyes (57.9%) showed active FVP. Thirty-four eyes (59.6%) had extent of RD involving 3 or 4 quadrants. The primary reattachment rate was 93.0%, and the final visual acuity (VA) improved by more than 3 lines in 80.7% of eyes. Neovascular glaucoma occurred in 4 eyes postoperatively. Poor preoperative VA, severe vitreoretinal adhesion, and broad extent of RD had significant correlation with poor visual outcomes. Conclusion. PRP or IVB might play a role in provoking combined RD. The anatomical and functional success rates of surgery were high. Poor preoperative VA and severe proliferations predicted poor visual outcomes.Entities:
Year: 2014 PMID: 25061523 PMCID: PMC4099346 DOI: 10.1155/2014/917375
Source DB: PubMed Journal: J Ophthalmol ISSN: 2090-004X Impact factor: 1.909
Clinical characteristics of enrolled patients.
| Case | Age (years) | Sex | Left/right eye | Comorbidities | Preop. PRP | Preop. IVB | Surgery | F/U period (months) | Anatomic outcome |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 54 | F | L | HTN | + | − | PPV + SB + SO | 13 | Attached |
| 2 | 47 | F | R | HTN | − | + | PPV + SO | 13 | Attached |
| 3 | 53 | F | L | — | − | − | Phaco + PPV + SB + SO | 22 | Attached |
| 4 | 43 | M | R | HTN | − | − | Phaco + PPV + SB + C3F8 | 60 | Recurrent RD |
| 5 | 48 | M | L | CAD | − | − | PPV + SB + SO | 46 | Attached |
| 6 | 51 | M | L | — | − | − | PPV + SB + SO | 17 | Attached |
| R | − | − | PPV + SB + SO | 15 | Attached | ||||
| 7 | 62 | M | L | HTN | − | − | PPV + SB + SO | 32 | Recurrent RD |
| 8 | 61 | M | R | HTN | − | − | Phaco + PPV + C3F8 | 17 | Attached |
| 9 | 52 | F | L | HTN | − | − | PPV + SB + SO | 14 | Attached |
| 10 | 63 | F | R | HTN | − | − | PPV + C3F8 | 35 | Attached |
| 11 | 54 | M | R | HTN, stroke | − | − | PPV + SB + C3F8 | 40 | Attached |
| 12 | 54 | M | L | HTN, CAD | − | − | Phaco + PPV + SB + SO | 60 | Attached |
| 13 | 60 | F | L | HTN, CAD | − | − | Phaco + PPV + SB + SO | 11 | Attached |
| 14 | 68 | F | R | HTN, stroke | − | − | PPV + SB + C3F8 | 35 | Attached |
| 15 | 62 | F | R | — | − | − | Phaco + PPV + SO | 8 | Attached |
| 16 | 56 | F | L | HTN | − | − | Phaco + PPV + SB + SO | 27 | Attached |
| 17 | 51 | F | L | HTN | − | − | PPV + SB + C3F8 | 55 | Recurrent RD |
| R | − | − | PPV + C3F8 | 32 | Attached | ||||
| 18 | 33 | M | R | HTN | + | − | PPV + SB + SO | 43 | Attached |
| 19 | 52 | F | R | HTN | + | + | PPV + SO | 26 | Attached |
| L | − | − | PPV + SO | 9 | Attached | ||||
| 20 | 29 | M | R | HTN | − | − | PPV + C3F8 | 8 | Attached |
| 21 | 52 | F | R | HTN | − | + | PPV + SB + C3F8 | 61 | Attached |
| 22 | 56 | F | L | HTN | − | + | PPV + SB + C3F8 | 5 | Attached |
| 23 | 52 | F | L | HTN, CKD | − | − | PPV + SB + SO | 31 | Attached |
| 24 | 47 | F | R | HTN | − | − | Phaco + PPV + SB + Retinectomy + SO | 22 | Attached |
| 25 | 55 | M | L | — | − | − | PPV + C3F8 | 34 | Attached |
| 26 | 55 | F | R | HTN | − | − | PPV + C3F8 | 26 | Attached |
| L | + | − | PPV + SB + SO | 12 | Attached | ||||
| 27 | 64 | F | R | HTN | − | − | PPV + SB + C3F8 | 48 | Attached |
| 28 | 63 | M | R | HTN | − | − | Phaco + PPV + SB + Retinectomy + SO | 5 | Attached |
| 29 | 57 | F | R | — | − | − | PPV + Retinectomy + SO | 17 | Attached |
| 30 | 65 | M | R | — | − | − | PPV + C3F8 | 48 | Attached |
| 31 | 30 | F | L | HTN | − | − | PPV + SB + SO | 10 | Attached |
| 32 | 54 | F | L | — | − | − | PPLV + SB + SO | 22 | Attached |
| 33 | 37 | M | R | HTN | + | − | PPV + C3F8 | 45 | Recurrent RD |
| L | − | + | PPV + SB + SO | 40 | Attached | ||||
| 34 | 50 | M | L | HTN, CKD | − | − | Phaco + PPV + SB + SO | 6 | Attached |
| 35 | 47 | F | L | HTN, CAD, CKD | − | − | PPV + C3F8 | 72 | Attached |
| R | − | − | PPV + C3F8 | 70 | Attached | ||||
| 36 | 74 | M | L | HTN, stroke, CAD | − | − | PPV + SB + C3F8 | 3 | Attached |
| 37 | 38 | F | L | HTN | − | − | PPV + SB + C3F8 | 19 | Attached |
| 38 | 47 | F | R | — | − | − | PPV + SB + SO | 5 | Attached |
| 39 | 50 | M | R | — | − | − | PPV + SB + C3F8 | 6 | Attached |
| 40 | 47 | M | R | — | − | − | PPV + C3F8 | 15 | Attached |
| 41 | 41 | F | L | — | − | − | Phaco + PPV + SB + SO | 26 | Attached |
| 42 | 50 | M | L | HTN | + | − | PPV + SB + SO | 17 | Attached |
| 43 | 51 | M | L | — | + | − | PPV + SB + C3F8 | 31 | Attached |
| 44 | 45 | M | R | HTN, CKD | − | − | PPV + SB + SO | 6 | Attached |
| 45 | 67 | M | L | HTN | + | − | Phaco + PPV + C3F8 | 8 | Attached |
| R | − | − | PPV + C3F8 | 6 | Attached | ||||
| 46 | 60 | F | R | HTN | − | − | PPV + SB + SO | 6 | Attached |
| L | − | − | PPV + SB + SO | 6 | Attached | ||||
| 47 | 53 | F | R | — | − | + | PPV + C3F8 | 8 | Attached |
| 48 | 54 | F | R | HTN | − | − | PPV + SO | 8 | Attached |
| 49 | 56 | F | R | — | + | + | PPV + SB + SO | 6 | Attached |
CAD: coronary artery disease; CKD: chronic kidney disease; F: female; HTN: hypertension; M: male; phaco: phacoemulsification; PPV: pars plana vitrectomy; RD: retinal detachment; SB: scleral buckling; SO: silicone oil.
Clinical features and outcome of combined retinal detachment.
| Case | Left/right eye | Extent of RD (quadrant) | Severity of vitreoretinal adhesion (grade) | Vascular component of proliferative tissue (chronic fibrotic versus active fibrovascular proliferative) | Retinal breaks found preop. or not | Number of retinal breaks (single versus multiple breaks) | Preop. VA (logMAR) | Post-op. VA (logMAR) | Complication |
|---|---|---|---|---|---|---|---|---|---|
| 1 | L | 3 | 3 | Chronic | − | Multiple | 2 | 1.5 | — |
| 2 | R | 2 | 2 | Active | − | Multiple | 1.7 | 0.7 | RAO |
| 3 | L | 4 | 4 | Active | − | Multiple | HM/20 cm | CF/20 m | Foveal atrophy |
| 4 | R | 3 | 1 | Active | + | Multiple | HM/1 m | 1.7 | — |
| 5 | L | 3 | 3 | Chronic | + | Multiple | 2 | 0.7 | — |
| 6 | L | 2 | 3 | Active | − | Multiple | 2 | 1 | — |
| R | 4 | 4 | Chronic | + | Multiple | HM/1 m | NLP | NVG | |
| 7 | L | 3 | 2 | Chronic | + | Multiple | CF/70 cm | 1 | — |
| 8 | R | 1 | 1 | Chronic | + | Multiple | 1 | 0.3 | Recurrent VH |
| 9 | L | 2 | 4 | Chronic | + | Multiple | CF/30 cm | 1.3 | — |
| 10 | R | 1 | 1 | Active | − | Single | 0.7 | 0.22 | — |
| 11 | R | 2 | 2 | Active | + | Multiple | 1.5 | 0.52 | NVG |
| 12 | L | 3 | 2 | Chronic | + | Single | 1.3 | 1.4 | — |
| 13 | L | 4 | 4 | Chronic | − | Single | 1.3 | 0.82 | — |
| 14 | R | 3 | 3 | Active | − | Single | 1.3 | 1 | — |
| 15 | R | 2 | 4 | Chronic | − | Single | HM/30 m | 1.52 | — |
| 16 | L | 3 | 4 | Chronic | + | Single | HM/1 m | 0.7 | ERM |
| 17 | L | 3 | 4 | Chronic | − | Multiple | 0.52 | 1.3 | Foveal atrophy |
| R | 1 | 1 | Chronic | + | Single | 1.7 | 1 | — | |
| 18 | R | 3 | 3 | Active | + | Single | 1.7 | 0.52 | — |
| 19 | R | 4 | 3 | Chronic | + | Single | CF/30 cm | 1.3 | — |
| L | 4 | 3 | Active | − | Multiple | HM/50 cm | HM/1 m | — | |
| 20 | R | 4 | 3 | Active | − | Single | CF/20 cm | 0.7 | — |
| 21 | R | 2 | 3 | Chronic | − | Multiple | 0.7 | 0.82 | — |
| 22 | L | 2 | 2 | Active | + | Single | 0.82 | 0.52 | Recurrent VH, RAO |
| 23 | L | 3 | 3 | Active | − | Single | 2 | 1 | ERM |
| 24 | R | 2 | 4 | Active | − | Multiple | 2 | 1.7 | — |
| 25 | L | 4 | 3 | Active | − | Multiple | HM/30 cm | 0.7 | — |
| 26 | R | 1 | 3 | Active | + | Multiple | 0.52 | 0.22 | — |
| L | 3 | 3 | Active | + | Single | 1.7 | 0.82 | NVG | |
| 27 | R | 2 | 2 | Active | − | Multiple | 2 | 1 | — |
| 28 | R | 4 | 3 | Active | − | Single | CF/60 cm | CF/60 cm | — |
| 29 | R | 4 | 4 | Active | − | Single | 2 | HM/40 cm | NVG |
| 30 | R | 2 | 2 | Chronic | − | Single | 2 | 1.3 | — |
| 31 | L | 4 | 3 | Active | + | Single | HM/1 m | 1.3 | — |
| 32 | L | 4 | 4 | Active | + | Multiple | HM/10 cm | HM/30 cm | — |
| 33 | R | 3 | 3 | Active | + | Single | 1.7 | 1.3 | — |
| L | 3 | 3 | Active | − | Multiple | CF/50 cm | 1 | — | |
| 34 | L | 4 | 4 | Chronic | − | Multiple | CF/30 cm | 1.3 | — |
| 35 | L | 2 | 2 | Active | − | Single | 2 | 0.7 | — |
| R | 2 | 2 | Active | − | Multiple | 0.4 | 0.82 | ERM | |
| 36 | L | 2 | 2 | Active | + | Multiple | HM/1 m | 1.7 | — |
| 37 | L | 4 | 1 | Chronic | − | Multiple | 1.7 | 1 | — |
| 38 | R | 3 | 4 | Active | − | Multiple | 1.7 | 1.52 | — |
| 39 | R | 1 | 2 | Active | − | Multiple | 1.52 | 1.7 | — |
| 40 | R | 2 | 2 | Active | + | Multiple | CF/50 cm | 0.52 | — |
| 41 | L | 4 | 1 | Chronic | + | Single | HM/50 m | CF/60 cm | — |
| 42 | L | 4 | 2 | Chronic | + | Multiple | CF/20 cm | 1.7 | — |
| 43 | L | 4 | 3 | Active | − | Single | HM/1 m | 0.82 | — |
| 44 | R | 3 | 3 | Chronic | + | Multiple | HM/60 cm | 1.3 | — |
| 45 | L | 2 | 3 | Chronic | − | Single | 1.5 | 0.82 | ERM |
| R | 1 | 3 | Active | − | Single | 1.3 | 0.7 | — | |
| 46 | R | 4 | 3 | Chronic | + | Single | 1.7 | 1.3 | — |
| L | 4 | 3 | Chronic | + | Single | 1.3 | 0.7 | — | |
| 47 | R | 2 | 3 | Active | − | Single | 0.7 | 0.22 | — |
| 48 | R | 4 | 3 | Active | + | Multiple | HM/1 m | CF/40 cm | — |
| 49 | R | 2 | 2 | Chronic | + | Single | 1.6 | 0.82 | — |
CF: counting fingers; ERM: epiretinal membrane; HM: hand motion; NLP: nonlight perception; NVG: neovascular glaucoma; RAO: retinal artery occlusion; VH: vitreous hemorrhage.
The severity of vitreoretinal adhesion was defined as multiple-point adhesions with or without 1-site-wide plaque-like adhesion (Grade 1), broad adhesions in more than 1 but fewer than 3 sites posterior to equator (Grade 2), broad adhesions in more than 3 sites posterior to equator or 1 site anterior to equator (Grade 3), and broad adhesions more than 1 site anterior to equator (Grade 4).
Figure 1(a–d) Case 47 (right eye). (a) Preoperative fundus photo showed active fibrovascular proliferation of Grade 3 severity; (b) preoperative optical coherence tomography showed detached retina; (c) postoperative fundus photo showed retinal attachment 2 months after surgery; (d) postoperative OCT revealed flat central retina with residual subretinal fluid pockets. (e–h) Case 19 (right eye). (e) Preoperative fundus photo showed chronic fibrosis of Grade 3 severity. A large oval-shaped retinal break at temporal side was noted; (f) preoperative OCT showed elevated retina at the macular area; (g) postoperative fundus photo showed retinal attachment with silicone oil tamponade 1 month after surgery; (h) postoperative OCT revealed attached retina with thin epimacular membrane.
Regression analyses of risk factors associated with poor postoperative visual outcomes.
| Predictive factors | Simple regression | Adjustment for age, sex, and preoperative BCVA | ||
|---|---|---|---|---|
| Coefficient |
| Coefficient |
| |
| Age | 0.0003 | 0.98 | — | — |
| Sex (F versus M) | −0.085 | 0.66 | — | — |
| Preoperative BCVA | 0.558 | 0.002∗ | — | — |
| Preoperative PRP | 0.062 | 0.77 | −0.017 | 0.92 |
| Preoperative IVB | −0.085 | 0.09 | 0.016 | 0.93 |
| Severity of vitreoretinal adhesion (Grade ≤ 3 versus Grade 4) | 0.697 | 0.01∗ | 0.502 | 0.04∗ |
| Vascular component of proliferative tissue (chronic fibrotic versus active fibrovascular) | −0.050 | 0.80 | −0.008 | 0.96 |
| Extent of RD | 0.358 | 0.002∗ | 0.248 | 0.03∗ |
| Retinal breaks found preoperatively or not | 0.059 | 0.76 | −0.074 | 0.66 |
| Number of retinal breaks (single break versus multiple breaks) | 0.251 | 0.21 | 0.242 | 0.17 |
| Intraoperative retinectomy | 0.854 | 0.02∗ | 0.681 | 0.04∗ |
| Silicone oil use | 0.593 | 0.01∗ | 0.326 | 0.12 |
| Combined scleral buckling | 0.301 | 0.16 | 0.188 | 0.30 |
| Combined cataract surgery | 0.199 | 0.34 | 0.197 | 0.28 |
| Recurrent RD with secondary PPV | 0.334 | 0.33 | 0.357 | 0.24 |
BCVA: best corrected visual acuity; IVB: intravitreal bevacizumab; RD: retinal detachment; PRP: panretinal photocoagulation.
*P < 0.05 was considered to be statistically significant.
Comparison of the present study and the previous study.
| Current study | Yang et al., 2008 [ |
| |||
|---|---|---|---|---|---|
| Eyes (patients) | 57 (49) | 40 (36) | — | ||
| Age (years) [mean ± SD (range)] | 52.4 ± 9.4 (29–74) | 54.7 ± 11.3 (25–70) | 0.14 | ||
| Active : chronic (ratio) | 33 : 24 (1.38) | 19 : 21 (0.90) | 0.31 | ||
| Multiple breaks [ | 30 (52.6) | 12 (30) | 0.03∗ | ||
| Break(s) noted before surgery [ | 27 (47.4) | 7 (17.5) | 0.002∗ | ||
| Extent of FVP | 0.35 | ||||
| Grade 1 [ | 6 (10.5) | 5 (12.5) | |||
| Grade 2 [ | 13 (22.8) | 14 (35) | |||
| Grades 3 and 4 [ | 38 (66.7) | 21 (52.5) | |||
| Extent of RD | 0.09 | ||||
| Total [ | 19 (33.3) | 22 (55) | |||
| Subtotal [ | 32 (56.1) | 14 (35) | |||
| Localized [ | 6 (10.5) | 4 (10) | |||
| Primary retina reattachment [ | 53 (93.0) | 37 (92.5) | 0.93 | ||
| Post-op VA | |||||
| Improved | 46 (80.7) | 28 (70) | Improved | 28 (70) | 0.57 |
| Unchanged | 6 (10.5) | 6 (15) | Unchanged | 6 (15) | |
| Worse | 5 (8.8) | 6 (15) | Worse | 6 (15) | |
| Post-op VA ≥ 0.05 [ | 40 (70.2) | 19 (47.5) | 0.02∗ | ||
| Post-op NVG [ | 4 (7.0) | 3 (7.5) | 0.93 | ||
FVP: fibrovascular proliferation; OP: operation; RD: retinal detachment; VA: visual acuity. Statistical analyses of noncontinuous variables were performed with chi-squared test as appropriate, and continuous variables were performed with two-sample t-test. *P value of less than 0.05 was considered statistically significant.